Advertisement

Pharmacy World and Science

, Volume 25, Issue 5, pp 197–202 | Cite as

Opinion and behaviour of pharmacists towards the substitution of branded drugs by generic drugs: survey of 1,000 French community pharmacists

  • B. Allenet
  • H. Barry
Article

Abstract

Objective: In 1999, a new law was introduced, giving French pharmacists the right to switch from branded to generic drugs, unless the prescriber had specified that substitution was not permitted. The purpose of this study was to assess the opinion and behaviour of community pharmacists towards substitution.Design: Self‐completion, postal close‐ended questionnaires were filled out.Sample and setting: 1,000 French community pharmacists were includedResults: 90% of the pharmacists were favourable to the implementation of the substitution right. 42.5% declared they systematically offered patients the generic drug, whereas 55% chose to target specific populations for substitution. The reluctance of pharmacists could be commercial ('How do I get paid for the time spent? Is it worth risking loosing a customer?'), or cultural ('How do I work this out? Who should I offer generic drugs to? What strategy should I use to offer them?').Conclusion: Generic drug distribution is very recent in France and is not yet common practice. Pharmacists and patients must be informed and trained because substitution is a collaborative act. It does not depend solely on the will and experience of pharmacists.

Behaviour Community pharmacist France Generic drugs Opinion Professional identity Strategy Substitutio 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Decree No. 99–486 of 11 June 1999.Google Scholar
  2. 2.
    Meunier J, Thuillier A. Generic drugs and right of substitution. Relating to the article of the 1999 Social Security Financing Act. Ann Pharm Fr 1999; 57(4): 340–8.Google Scholar
  3. 3.
    Arrêté du 28 avril 1999 relatif aux marges des médicaments remboursables [Article of 28 April 1999 related to the margin of drugs reimbursed by French Social Security.] Journal Officiel of 29 April 1999: 6386–8.Google Scholar
  4. 4.
    Martin E, Rupprecht F. Les enjeux du médicament générique. [The stakes of generic drugs.] Economie et Statistique 1998; 312–313: 55–66.Google Scholar
  5. 5.
    Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000; 51(3): 149–62.Google Scholar
  6. 6.
    Rubak SL, Andersen ML, Mainz J et al. How do pharmacists evaluate the newly introduced system of substitution prescriptions ? Ugeskr Laeger 2000; 162(45): 6074–7.Google Scholar
  7. 7.
    Andersen ML, Laursen K, Shaumann M et al. How do patients evaluate the newly introduced system of substitution prescriptions ? Ugeskr Laeger 2000; 162(45): 6066–9.Google Scholar
  8. 8.
    Rubak SL, Andersen ML, Mainz J et al. How do practitioners evaluate the newly introduced system of substitution prescriptions ? Ugeskr Laeger 2000; 162(45): 6070–3.Google Scholar
  9. 9.
    Nordling S, Lindberg G, Sandberg C, Annel A, Melander A, Rydberg T. Hur gick försöket med generisk substitution i Skane? Stockholm: Apotekarsocietetens Förlag, 2000.Google Scholar
  10. 10.
    Barry H, Allenet B. Analyse des conditions d'intégration des produits génériques dans les officines. Proposition d'une typologie comportementale des pharmaciens. [Analysis of the conditions of generic drugs integration in pharmacies. Proposition for a pharmacist behaviour typology.] Les Nouvelles Pharmaceutiques 2001; 373: 557–562.Google Scholar
  11. 11.
    Statistiques de l'Ordre National des Pharmaciens au 1er janvier 2000 [Figures of the French National Board of Pharmacists, 1 January 2000] (http://www.ordre.pharmacien.fr).Google Scholar
  12. 12.
    Norgaard, LS, Colberg L, Niemann MR. The role of the Danish community pharmacist: perceptions and future scenarios. Pharm World Sci 2001; 23(4): 159–164.Google Scholar
  13. 13.
    Rubak SL, Andersen ML, Mainz J et al. How do pharmacists evaluate the newly introduced system of substitution prescriptions ? Ugeskr Laeger 2000; 162(45): 6074–7.Google Scholar
  14. 14.
    Allaert FA. Evolution de l'image des médicaments génériques dans la population française de 1996 à 1997. [Evolution of the image of generic drugs among the French population from 1996 to 1997.] J Econ Med 1998; 16(1): 93–96.Google Scholar
  15. 15.
    Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for prescription drugs. J Am Pharm Assoc 2000; 40(3): 378–383.Google Scholar
  16. 16.
    Andersen ML, Laursen K, Shaumann M et al. How do patients evaluate the newly introduced system of substitution prescriptions ? Ugeskr Laeger 2000; 162(45): 6066–9.Google Scholar
  17. 17.
    Rubak SL, Andersen ML, Mainz J et al. How do practitioners evaluate the newly introduced system of substitution prescriptions ? Ugeskr Laeger 2000; 162(45): 6070–3.Google Scholar
  18. 18.
    Pelton LE, Strutton D, Smith MC. A political economy perspective: why pharmacists may be reluctant to dispense generic medications. J Hosp Mark 1994; 9(1): 137.Google Scholar
  19. 19.
    Suth DC. Trends of generic substitution in community pharmacies. Pharm World Sci 1999; 21(6): 260–5.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • B. Allenet
    • 1
    • 2
  • H. Barry
    • 3
  1. 1.Clinical Pharmacy DepartmentGrenoble School of PharmacyFrance
  2. 2.Pavillon Moidieu, CHU de GrenobleTroncheFrance E‐mail
  3. 3.CRESGE‐Labores, URA362 CNRSLille CedexFrance

Personalised recommendations